1 4d Molecular Therapeutics Inc Receivables Turnover Ratio (FDMT), from the second quarter 2026 to the second quarter 2025 current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
4d Molecular Therapeutics Inc   (NASDAQ: FDMT)
 

4d Molecular Therapeutics Inc Accounts Receivables Turnover Ratio from the second quarter 2026 to the second quarter 2025

Quarterly Results, Trends, Rankings, Statistics


According to 4d Molecular Therapeutics Inc Balance Sheet, in the second quarter 2026, company has not reported any Accounts receivable.
See 4d Molecular Therapeutics Inc Balance Sheet

If we take a look into Healthcare sector 436 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2026 from 2674 to 2907.

What is Receivable Turnover Ratio?
What is 4d Molecular Therapeutics Inc Selling?


What is Receivable Turnover Ratio?




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

FDMT Receivables Turnover Ratio (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Receivable Change - - - - -
Y / Y Revenue Change 25106.67 % 21664.29 % 8508900 % 2900 % 200 %
Receivable Turnover Ratio (TTM) - - - - -
FDMT's Total Ranking # 2907 # 2674 # 2472 # 0 # 3595
Accounts Receivable average collection period days - - - - -
Seq. Receivable Change - - - - -
Seq. Revenue Change 24.09 % -96.42 % 94444.44 % 500 % 7.14 %


Receivable Turnover Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 39
Healthcare Sector # 437
Overall Market # 2907

Receivable Turnover Ratio Statistics
High Average Low
0.18 0.05 0
(Jun 30 2026)   (Sep 30 2024)





FDMT Company Profile • Back to FDMT Efficiency Comparisons • Compare FDMT Receivables Turnover Ratio to its Competitors

Financial Statements
4d Molecular Therapeutics Inc 's Accounts Receivable $ 0 Millions Visit FDMT's Balance sheet
4d Molecular Therapeutics Inc 's Sales TTM $ 92 Millions Visit FDMT's Income Statement
Sources of FDMT's Revenues Visit FDMT's Sales by Geography

Other Accounts Receivable Turnover Ratios
Biotechnology & Pharmaceuticals Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
FDMT's Receivable Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
FDMT's Growth Rates FDMT's Roa FDMT's Inventory Turnover Ratio FDMT's Dividend Comparisons
FDMT's Profitability Ratios FDMT's Roi FDMT's Asset Turnover Ratio FDMT's Dividend Growth
FDMT's Valuation Ratios FDMT's Roe FDMT's Financial Strength Ratios FDMT's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Jun 30 2026 Receivable at quarter ending Jun 30 2026

Date modified: 2026-09-03T11:45:51+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.